M. Paul, D. Yahav, A. Fraser, and L. Leibovici, Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials, Journal of Antimicrobial Chemotherapy, vol.57, issue.2, pp.176-89, 2006.
DOI : 10.1093/jac/dki448

M. Fletcher, H. Hodgkiss, S. Zhang, R. Browning, C. Hadden et al., Prompt administration of antibiotics is associated with improved outcomes in febrile neutropenia in children with cancer, Pediatric Blood & Cancer, vol.386, issue.8, pp.1299-306, 2013.
DOI : 10.1002/pbc.24485

A. Manji, T. Lehrnbecher, L. Dupuis, J. Beyene, and L. Sung, A systematic review and meta-analysis of anti-pseudomonal penicillins and carbapenems in pediatric febrile neutropenia, Supportive Care in Cancer, vol.3, issue.Suppl 2, pp.2295-304, 2012.
DOI : 10.1007/s00520-011-1333-3

A. Manji, T. Lehrnbecher, L. Dupuis, J. Beyene, and L. Sung, A Meta-analysis of Antipseudomonal Penicillins and Cephalosporins in Pediatric Patients With Fever and Neutropenia, The Pediatric Infectious Disease Journal, vol.31, issue.4, pp.353-361, 2012.
DOI : 10.1097/INF.0b013e318242590e

T. Lehrnbecher, R. Phillips, A. S. Alvaro, F. Carlesse, F. Fisher et al., Guideline for the Management of Fever and Neutropenia in Children With Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation, Journal of Clinical Oncology, vol.30, issue.35, pp.4427-4465, 2012.
DOI : 10.1200/JCO.2012.42.7161

E. Orudjev and B. Lange, Evolving concepts of management of febrile neutropenia in children with cancer, Medical and Pediatric Oncology, vol.341, issue.2, pp.77-85, 2002.
DOI : 10.1002/mpo.10073

L. Sung, R. Phillips, and T. Lehrnbecher, Time for paediatric febrile neutropenia guidelines ??? children are not little adults, European Journal of Cancer, vol.47, issue.6, pp.811-814, 1990.
DOI : 10.1016/j.ejca.2011.01.021

P. Furno, G. Bucaneve, D. Favero, and A. , Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis, The Lancet Infectious Diseases, vol.2, issue.4, pp.231-273, 2002.
DOI : 10.1016/S1473-3099(02)00241-4

F. Corapcioglu, N. Sarper, and E. Zengin, MONOTHERAPY WITH PIPERACILLIN/TAZOBACTAM VERSUS CEFEPIME AS EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIA IN PEDIATRIC CANCER PATIENTS: A Randomized Comparison, Pediatric Hematology and Oncology, vol.6, issue.3, pp.177-86, 2006.
DOI : 10.1179/joc.2001.13.3.281

A. Hamidah, A. Rizal, A. Nordiah, and R. Jamal, Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients, Singapore Med J, vol.49, issue.1, pp.26-30, 2008.

E. Zengin, N. Sarper, and S. K?l?ç, Piperacillin/Tazobactam Monotherapy Versus Piperacillin/Tazobactam Plus Amikacin as Initial Empirical Therapy for Febrile Neutropenia in Children with Acute Leukemia, Pediatric Hematology and Oncology, vol.44, issue.3, pp.311-331, 2011.
DOI : 10.1086/496927

M. Paul, Y. Dickstein, A. Schlesinger, S. Grozinsky-glasberg, K. Soares-weiser et al., Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia, Cochrane Database Syst Rev, vol.6, p.3038, 2013.

M. Douard, E. Desruennes, I. Kriegel, and F. Blot, Complications of central venous and indwelling catheterization, Rev Prat, vol.56, issue.12, pp.1281-1290, 2006.

E. Protocole, Protocole multicentrique de traitement des leucémies aiguës myéloblastiques de l'enfant et de l'adolescent. Etude randomisée d'un traitement d'entretien par Interleukine 2 (Proleukine)

F. Protocole, Protocole de traitement des leucémies aiguës lymphoblastiques de la lignée B de risque standard de l'enfant. SFCE. Version finale 01 Investigateur principal, 2000.

G. Donowitz, D. Maki, C. Crnich, P. Pappas, and K. Rolston, Infections in the Neutropenic Patient-- New Views of an Old Problem, Hematology, vol.2001, issue.1, 2001.
DOI : 10.1182/asheducation-2001.1.113

D. Pauw, B. Walsh, T. Donnelly, J. Stevens, D. Edwards et al., Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group, Clinical Infectious Diseases, vol.46, issue.12, pp.1813-1834, 2008.
DOI : 10.1086/588660

G. Fleischhack, M. Schmidt-niemann, B. Wulff, W. Havers, G. Marklein et al., Piperacillin, beta-lactam inhibitor plus gentamicin as empirical therapy of a sequential regimen in febrile neutropenia of pediatric cancer patients, Support Care Cancer, vol.9, issue.5, pp.372-381, 2001.

M. Gorschlüter, C. Hahn, A. Fixson, U. Mey, C. Ziske et al., Piperacillintazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison, Support Care Cancer, vol.11, issue.6, pp.362-70, 2003.

J. Borbolla, M. López-hernández, M. González-avante, J. Dediego, E. Trueba et al., Comparison of Cefepime versus Ceftriaxone-Amikacin as Empirical Regimens for the Treatment of Febrile Neutropenia in Acute Leukemia Patients, Chemotherapy, vol.47, issue.5, pp.381-385, 2001.
DOI : 10.1159/000048547

P. Furno, M. Dionisi, G. Bucaneve, F. Menichetti, D. Favero et al., Ceftriaxone versus ??-lactams with antipseudomonal activity for empirical, combined antibiotic therapy in febrile neutropenia: a meta-analysis, Supportive Care in Cancer, vol.8, issue.4, pp.293-301, 2000.
DOI : 10.1007/s005200000105

M. Paul, Y. Dickstein, S. Borok, L. Vidal, and L. Leibovici, Empirical antibiotics targeting Gram-positive bacteria for the treatment of febrile neutropenic patients with cancer, Cochrane Database Syst Rev, vol.55, issue.4, p.3914, 2014.
DOI : 10.1002/14651858.CD003914.pub3

A. Cometta, W. Kern, D. Bock, R. Paesmans, M. Vandenbergh et al., Vancomycin versus Placebo for Treating Persistent Fever in Patients with Neutropenic Cancer Receiving Piperacillin-Tazobactam Monotherapy, Clinical Infectious Diseases, vol.37, issue.3, pp.382-391, 2003.
DOI : 10.1086/376637

V. Uygun, G. Karasu, D. Ogunc, A. Yesilipek, and V. Hazar, Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: A randomized and open-label study, Pediatric Blood & Cancer, vol.9, issue.4, pp.610-614, 2009.
DOI : 10.1002/pbc.22100

E. Bow, C. Rotstein, G. Noskin, M. Laverdiere, A. Schwarer et al., A Randomized, Open-Label, Multicenter Comparative Study of the Efficacy and Safety of Piperacillin-Tazobactam and Cefepime for the Empirical Treatment of Febrile Neutropenic Episodes in Patients with Hematologic Malignancies, Clinical Infectious Diseases, vol.43, issue.4, pp.447-59, 2006.
DOI : 10.1086/505393

D. Favero, A. Menichetti, F. Martino, P. Bucaneve, G. Micozzi et al., A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia, Clin Infect Dis, vol.33, issue.8, pp.1295-301, 2001.

K. Vardakas, G. Samonis, S. Chrysanthopoulou, I. Bliziotis, and M. Falagas, Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials, The Lancet Infectious Diseases, vol.5, issue.7, pp.431-440, 2005.
DOI : 10.1016/S1473-3099(05)70164-X

M. Paul, S. Borok, A. Fraser, L. Vidal, and L. Leibovici, Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials, Journal of Antimicrobial Chemotherapy, vol.55, issue.4, pp.436-480, 2005.
DOI : 10.1093/jac/dki028

A. Tiphaine and . Droit-et-de-la-santé, Quelle est la prise en charge ré elle des neutropé nies fé briles post-chimiothé rapie de l'enfant ré sultats d'une enque? te franc? aise, 2013.

M. Delebarre, E. Macher, F. Mazingue, A. Martinot, and F. Dubos, Which decision rules meet methodological standards in children with febrile neutropenia? Results of a systematic review and analysis, Pediatr Blood Cancer, issue.10, pp.611786-91, 2014.

F. De, M. De-brest-52, and T. Henry, Chloé) -impact de la Tazocilline® dans la prise en charge des neutropénies fébriles, expérience du service de pédiatrie du centre hospitalier universitaire de Brest. 51 f, 2 tabl, 5 fig

. Résumé, une pathologie maligne. L'objectif principal de ce travail était l'évaluation d'un nouveau protocole d'antibiothérapie, par Tazocilline®, dans le traitement des neutropénies fébriles en oncologie pédiatrique dans le service de pédiatrie du centre hospitalier universitaire (CHU) de Brest Etude de comparaison historique, réalisée dans le service de pédiatrie du CHU de Brest. Comparaison d'un nouveau protocole à l'ancien appliqué dans le service afin d'évaluer son efficacité et sa tolérance, Pas de différence de succès ou d'échec du nouveau protocole en comparaison à l'ancien et pas de différence sur le plan des complications. L'utilisation de la Tazocilline® en monothérapie dans le traitement de la neutropénie fébrile en oncologie pédiatrique semble possible mais il n'existe encore que peu de connaissances à son sujet chez l'enfant